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Abstract
HIV vaccine development has been hampered by issues such as undefined correlates of protection and extensive diversity
of HIV. We addressed these issues using a previously established SIV-macaque model in which SIV mutants with deletions of
multiple gp120 N-glycans function as potent live attenuated vaccines to induce near-sterile immunity against the parental
pathogenic SIVmac239. In this study, we investigated the protective efficacy of these mutants against a highly pathogenic
heterologous SIVsmE543-3 delivered intravenously to rhesus macaques with diverse MHC genotypes. All 11 vaccinated
macaques contained the acute-phase infection with blood viral loads below the level of detection between 4 and 10 weeks
postchallenge (pc), following a transient but marginal peak of viral replication at 2 weeks in only half of the challenged
animals. In the chronic phase, seven vaccinees contained viral replication for over 80 weeks pc, while four did not.
Neutralizing antibodies against challenge virus were not detected. Although overall levels of SIV specific T cell responses did
not correlate with containment of acute and chronic viral replication, a critical role of cellular responses in the containment
of viral replication was suggested. Emergence of viruses with altered fitness due to recombination between the vaccine and
challenge viruses and increased gp120 glycosylation was linked to the failure to control SIV. These results demonstrate the
induction of effective protective immune responses in a significant number of animals against heterologous virus by
infection with deglycosylated attenuated SIV mutants in macaques with highly diverse MHC background. These findings
suggest that broad HIV cross clade protection is possible, even in hosts with diverse genetic backgrounds. In summary,
results of this study indicate that deglycosylated live-attenuated vaccines may provide a platform for the elucidation of
correlates of protection needed for a successful HIV vaccine against diverse isolates.
Citation: Sugimoto C, Watanabe S, Naruse T, Kajiwara E, Shiino T, et al. (2010) Protection of Macaques with Diverse MHC Genotypes against a Heterologous SIV
by Vaccination with a Deglycosylated Live-Attenuated SIV. PLoS ONE 5(7): e11678. doi:10.1371/journal.pone.0011678
Editor: Douglas F. Nixon, University of California San Francisco, United States of America
Received March 22, 2010; Accepted June 28, 2010; Published July 20, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This work was supported by AIDS research grants from the Health Sciences Research Grants, from the Ministry of Health, Labor, and Welfare in Japan,
and from the Ministry of Education, Culture, Sports, Science and Technology in Japan. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mori@nibio.go.jp
¤a Current address: Division of Immunology, Tulane National Primate Research Center, Covington, Louisiana, United States of America
¤b Current address: Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
Introduction
Molecular epidemiological studies have revealed the existence
of an extensive degree of diversity of HIV-1 isolates [1]. HIV-1 is
classified in three major groups (M, N, O) based on their
geographical origin. Group M represents the predominant HIV-1
circulating through the world and has been divided into more than
10 subtypes (clades) as well as increasing number of circulating
recombinant forms (CRF) primarily due to error-prone viral
reverse transcriptase and the occurrence of super-infections. This
diversity is continuously expanding worldwide and is a major
obstacle for the successful development of an AIDS vaccine. While
the generation of a vaccine capable to prevent transmission of
HIV isolates endemic in a particular area remains an unfulfilled
task, protection against phylogenetically distant viruses represents
an even more formidable hurdle. The failure and dismal success of
HIV-1 vaccine trials that have been conducted so far has
prompted a re-emphasis for more basic studies concerning vaccine
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11678design against heterologous challenge viruses, which can at present
only be addressed in a macaque model. One of the pre-conditions
for the objective assessment of the protective efficacy against a
heterologous strain would be that the macaque model used should
have the capacity to confer sterile or near-sterile immunity against
the homologous virus challenge.
SIVmac239 infected rhesus macaques gradually develop AIDS
after a variable period of chronic infection. In order to investigate
the role and function of the glycan shield of the viral envelope, we
previously developed a panel of deglycosylated mutants from this
pathogenic SIVmac239 backbone [2]. Among these mutants, one
mutant with five N-glycans deleted (D5G) was found to be
profoundly attenuated in rhesus macaques. Thus, while the acute
primary viremia showed viral peaks undistinguishable from those
measured in animals infected with the wild-type SIVmac239
infection, viral load during the chronic phase was contained at or
below the level of detection [3]. More importantly, these D5G
‘‘immunized’’ macaques during the chronic phase manifested
near-sterile immunity when challenged with the homologous wild-
type SIVmac239, and the animals showed neither evolution of
pathogenic revertants nor clinical disease manifestation during a
10 year follow up period. While it is clear that similar live
attenuated HIV-1 vaccines will not likely be utilized in humans, it
is extremely important to have an animal model that shows
protection against heterologous challenge virus so that minimally
such a model can be exploited to identify reproducible immune
correlates of protection. We therefore reasoned that our
SIVmac239-deglycosylation platform may provide an unique
opportunity to test and analyze protection against challenge with
heterologous isolates.
The studies reported herein utilized a series of four deglycosy-
lated SIVmac239 mutants as potential live attenuated vaccine
viruses and the SIVsmE543-3 isolate [4] as the heterologous
challenge virus. We submit that the diversities between the vaccine
viruses and the challenge virus are equivalent to those found
between major HIV-1 subtypes. Thus, this heterologous challenge
model provides an ideal model to assess the potential of and define
the conditions for cross-subtype (clade) protection against HIV.
The natural protective effects of select rhesus macaque (Mamu)
MHC class I alleles such as Mamu B*08, Mamu B*17, Mamu
A*01 and the MHC class I haplotype 90120-Ia have been shown
to be associated with better control of SIV [5,6,7,8,9]. In sharp
contrast, protection by the deglycosylated SIV mutants exhibited
no such selectivity; protection was achieved in all 9 rhesus
macaques tested so far, which were later found to be indeed
genetically highly diverse. Previous human cohort studies revealed
that individuals who demonstrated control of HIV infection
without any treatment, called long-term non-progressors and elite
controllers, have common genetic properties associated with
susceptibility to HIV or anti-viral host responses [10,11,12].
However, candidate vaccines that are aimed at targeting outbred
human population will have to show effectiveness in humans with
diverse genetic backgrounds. In order to minimize the contribu-
tion of particular positive or negative genetic background,
macaques possessing the above described elite genotypes were
therefore eliminated from the studies reported herein. Further-
more, the macaques were grouped based on the genetic data so
that each group comprised animals with an essentially similar
genetically diverse background.
We herein report data from a series of studies that support the
concept that cross-subtype control of HIV-1 is theoretically
possible irrespective of genetic background. Data derived herein
demonstrate a critical role that glycosylation plays in not only
conferring attenuation of SIV/HIV but also the potential role
glycosylation plays in conferring pathogenic properties to viruses
that emerge following challenge with heterologous viruses.
Results
Genetic diversity of the challenge virus from the vaccine
virus
SIVs are as diverse as the HIV-1 subtypes in group M, and at
present a total of 9 different SIV lineages have been identified
[13]. SIVmac239 belongs to lineage 8. We have generated a
variety of modified candidate live vaccine strains by the
introduction of deglycosylation mutations into multiple N-
glycosylation sites of the gp120 of SIVmac239 (Fig. 1). The
heterologous challenge virus used in this study is the molecularly
cloned pathogenic strain SIVsmE543-3 that belongs to lineage 1.
SIVmac239 and SIVsmE543-3 possess 23 and 22 N-glycosylation
sites, respectively, and as seen their topologies in the gp120 protein
backbones are almost the same (Fig. 1).
At first, we compared the amino acid sequence differences for
the individual viral proteins between SIVmac239 and
SIVsmE543-3 (Table 1). The genetic differences varied from
7.9% for Pol to 35.9% for Tat. We then compared the diversity
between the 2 SIV strains utilized herein with the intra-subtype or
inter-subtype diversities in the HIV-1 isolates and found that the
differences between SIVsmE543-3 and SIVmac239 were signifi-
cantly greater than any intra-subtype diversities of HIV-1
(Table 1). For the inter-subtype diversity analysis, we used
subtypes B and C and a circulating recombinant CRF01_AE as
reference strains that are predominantly circulating in Asian
countries. The data indicated that the differences between the two
SIV strains were as high or higher as those found among the three
HIV-1 subtypes. These results validate the use of SIVmac239 as
the parental virus for live attenuated vaccine virus and the
SIVsmE543-3 as the heterologous challenge virus in the rhesus
macaque model of human AIDS.
Properties of the 3 new deglycosylation mutants as live
attenuated candidate vaccines
We previously reported that D5G, a SIVmac239 molecular
clone with quintuple deglycosylation mutations behaved as a live-
attenuated virus in vivo [2,3]. In addition to D5G, we tested three
newly constructed deglycosylated mutants of SIVmac239 viruses,
D5G-ver1, D5G-ver2 and D3G as potential candidate vaccines in
this study (Fig. 1). They differ by the sites or numbers of N-
glycosylation sites mutated in gp120 (Fig. 1). All four deglycosy-
lated mutants replicated well in rhesus peripheral blood mononu-
clear cells (PBMC) in vitro, and the replication kinetics were
similar to SIVmac239 ([2], and data not shown). However,
differences were noted in the rate of replication in macrophage
cultures and sensitivity to neutralizing antibodies (NAb) (data not
shown). To investigate whether these differences translated into
altered in vivo properties such as viral replication kinetics in rhesus
macaques, reduced pathogenicity and potential vaccine properties,
12 animals were inoculated intravenously in groups of three with
100 TCID50 of each of the four mutants (Fig. 2 A). Since the
MHC types have been shown to significantly influence the
outcome of HIV/SIV infection in their respective hosts, we chose
macaques which did not inherit any of the known elite MHC
alleles [5,6,7,8,9] (File S1). Furthermore, to minimize the possible
influence of other MHC types, we distributed the animals evenly
into vaccine and control groups such that each group comprised
animals with randomized MHC alleles (File S1).
Consistent with our previous studies [3], the prototypic vaccine
strain D5G, replicated as robustly as the SIVmac239 in macaques
Deglycosylated SIV Vaccine
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7 copies/ml at 2 weeks
post infection (pi) (Figs. 2A and 3). However, subsequently the VL
of D5G rapidly declined to a level around or below the level of
detection (100 copies/ml) whereas relatively high VL persisted in
SIVmac239-infected macaques (Figs. 2A and 3). Essentially the
kinetics of viremia observed with the three deglycosylation
mutants, D5G-ver1, D5G-ver2 and D3G were similar to that seen
with D5G (Fig. 2 A).
It has been well established that SIVmac239 elicits poor NAb in
macaques [14]. In contrast, a deglycosylation mutant derived from
SIVmac239 elicited higher NAb than SIVmac239, but levels of
NAb responses varied among the animals [15]. Thus, we
determined levels of potential NAb responses against each animal’s
respective infecting virus. Consistent with our previous results,
most macaques infected with each of the deglycosylated SIVs
induced NAb (Fig. 2 B). However, the levels of NAb responses
differed among the four groups, with a decreasing order of
magnitude for NAb responses from D5G-ver2.D5G-
ver1.D3G.D5G. We detected no NAb response in two animals
(Mm0301 in the D5G group and Mm0304 in the D3G group), and
delayed and relatively weak responses in three animals (Mm0409
in the D5G group, Mm0511 in the D5G-ver1 group, and Mm0516
in the D3G group) (Fig. 2 B). Regardless of the levels of NAb, all 12
animals infected with the deglycosylation mutant viruses contained
Figure 1. Live attenuated vaccines with deglycosylation mutations. N-glycosylation sites (vertical bars) localized within gp120 of SIVmac239
and SIVsmE543-3 are shown. SIVmac239 and SIVsmE543-3 have 23 and 22 N-glycosylation sites, respectively. The position of N-glycosylation sites
mutated to remove the specific glycans for D5G, D5Gver-1, D5Gver-2, and D3G were indicated and constructed by site-directed mutagenesis based
on SIVmac239. V1 to V5 indicate variable region 1 to 5 respectively. C-loop indicates the constant loop region within SIVmac239 [15].
doi:10.1371/journal.pone.0011678.g001
Table 1. Differences between the vaccine and challenge SIV and inter-subtype differences of HIV-1.
Viral proteins SIV
b HIV
a
mac239 vs.
smE543-3
Intra-subtype (A, B, C, D, F1,
G, CRF01_AE, and CRF_02AG) Inter-subtype
B vs. C B vs. CRF01 C vs. CRF01
Mean S.E. Mean S.E. Mean S.E.
Gag 11.1 4.3–7.1 10.2 1.2 11 1.4 12.8 1.5
Pol 7.9 2.8–6.5 7.8 0.7 8 0.8 7.5 0.7
Env 18.2 7.7–12.4 19.2 1.4 18.8 1.4 18.7 1.4
Nef 26.2 9.0–16.2 22.6 4.8 21.3 4.8 16.2 3.5
Tat 35.9 9.9–18.1 28.8 4.7 31.9 4.9 27.4 4.3
Rev 32.7 9.0–16.5 28.3 4.7 26.4 4.7 20.6 4.1
Vif 17.8 7.0–14.2 20.5 2.6 21.6 2.9 21.3 2.8
Vpr 14.9 5.4–10.6 13.1 3.2 13 3.4 5 3.5
Vpx 8.1 NA
c NA NA NA
Vpu NA 2.4–14.8 17.7 5.6 3.8 5.4 12.7 3
aPercentage amino acid sequence differences per site from averaging overall sequence pairs between the subtypes.
bPercent amino acid sequence differences per protein.
cNot applicable.
doi:10.1371/journal.pone.0011678.t001
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NAb were most likely not a critical factor for containment of the
acute infection in these animals.
We previously found that animals vaccinated with D5G
completely resist infection when challenged with the parental
pathogenic SIVmac239 [3], showing minimal if any replication of
the challenge virus for more than 10 years. A similar homologous
challenge was performed in a subset of animals that received the
deglycosylation mutants in the present study. Thus, one of the
three ‘‘immunized’’ animals from each group was challenged with
a high dose (1000 TCID50) SIVmac239 at 40 weeks following
‘‘vaccination’’ and plasma viral loads were determined (Fig. 3). As
previously reported with D5G, a near-sterile immunity against
challenge with SIVmac239 was not only noted with the D5G but
also seen with our other three new deglycosylated SIV mutants,
D5G-ver1, D5G-ver2 and D3G (Fig. 3). These results indicate that
all 3 new vaccine versions possess similar equally high protective
potential against the homologous, wild type SIVmac239 as the
original D5G.
Protection of the vaccinated macaques against
heterologous challenge infection
The remaining eight animals (2 per group) vaccinated with each
of the 4 vaccine versions (D5G, D5G-ver1, D5G-ver2 or D3G) and
3 of the four animals that were vaccinated (described in the above
paragraph) and challenged with SIVmac239 (Mm0307 died of
SIV unrelated causes) were challenged with a high dose (1000
TCID50) of SIVsmE543-3 delivered intravenously. Additional
three naı ¨ve animals served as a control for this heterologous
challenge experiment (Fig. 4 A). VL were monitored until 80
weeks post challenge (pc) using real time RT-PCR primer pairs
and probes that distinguished the detection of SIVmac239 and
SIVsmE543-3.
The 3 naı ¨ve control macaques infected with SIVsmE543-3
exhibited a peak VL of ,10
7 copies/ml at 2 weeks pi which is
essentially similar to those we have routinely noted following
infection with SIVmac239 with a few exceptions. Notably, the set
point VL in SIVsmE543-3 was more than 10
5 copies/ml in 2
animals which is at least 1-log higher than that noted in animals
infected with SIVmac239 (Figs. 3 and 4 A). We reason that
SIVsmE543-3 is likely to be more pathogenic than SIVmac239 for
Figure 2. Viral loads and neutralizing antibodies in macaques infected with each of 4 deglycosylated SIV mutants. Twelve animals
were divided into 4 groups consist of 3 animals each and infected with each of 4 deglycosylation mutants (D5G, D5Gver-1, D5Gver-2, and D3G). (A)
Plasma viral loads were determined by real-time RT-PCR with SIVmac239 primers and probe set. (B) NAb responses against each respective infecting
virus were measured in CEMx174/SIVLTR-SEAP system. NAb titers were indicated as the reciprocal of the dilutions of the plasma from the vaccinees
yielding 50% inhibition (IC50).
doi:10.1371/journal.pone.0011678.g002
Figure 3. Plasma viral RNA loads in the homologous SIV-
mac239 challenge. Three naı ¨ve rhesus macaques (Mm0608, Mm0521,
Mm0522) and 4 vaccinees (Mm0301, Mm0304, Mm0513, Mm0307), i.e.
one animal from 4 deglycosylated SIV infection groups, were
challenged intravenously with 1000 TCID50 of SIVmac239. Plasma viral
loads were determined by real-time RT-PCR with SIVmac239 primers
and probe set.
doi:10.1371/journal.pone.0011678.g003
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AIDS and were euthanized at 46 weeks pi, which is significantly
faster than the time that we have noted for disease progression
following SIVmac239-infection of these Burmese monkeys
[3,8,15,16,17].
All 11 vaccinated animals contained the primary challenge with
SIVsmE543-3 (Figs. 4A, B, and C). At 2 weeks pc, average VL for
the vaccine groups were .3-log lower than those of naı ¨ve control
animals (Fig. 4D). Thus, 5 of the 11 vaccinated animals (Mm0511,
Mm0515, Mm0301, Mm0518, and Mm0304) contained the acute
challenge below the level of detection (100 copies/ml) at all times,
3 animals (Mm0303, Mm0516, and Mm0409) showed marginal
replication of SIVsm543-3 (329–700 copies/ml) during weeks 1–3
pc, while the other 3 animals (Mm0517, Mm0512, and Mm0513)
showed viremia with 1–3610
4 copies/ml during weeks 1–3 pc but
these replication peaks were transient and by 4 weeks pc, all
vaccinated animals controlled SIVsmE543-3 to undetectable levels
(Figs. 4B, C and D). Interestingly, transient replication of the
vaccine viruses was also detected in 6 animals after the
SIVsmE543-3 challenge (Mm0517, Mm0511, Mm0512,
Mm0515, Mm0409, and Mm0304) (Figs. 4 B and C), suggesting
reactivation of the deglycoylated virus upon super-infection with
SIVsmE543-3. Statistical analysis of these data led us to conclude
that the vaccinated animals significantly controlled SIVsmE543-3
replication at least during the acute phase up to 10 weeks pc
irrespective of their MHC genotypes (Fig. 4 D). These results,
taken together indicate that each of the deglycosylated vaccines
utilized has the potential of inducing protective immunity against a
potentially highly pathogenic heterologous challenge virus.
We next evaluated the containment of the challenge virus
infection during the chronic-phase compared with the one
observed after homologous challenge with SIVmac239 (Fig. 3
and ref [3]). Based on longitudinal VL (of either vaccine or
challenge virus), the vaccinated animals were divided into two
groups. One group of 7 animals, which we termed as
‘‘controllers’’, comprised animals which controlled the challenge
virus almost completely for the 80 weeks of follow-up pc (Fig. 4 B).
Detailed analyses of VL showed complete control of the
SIVsmE543-3 challenge in two of the animals (Mm0301 and
Mm0515) over time. Similar potent antiviral control (except for
small VL peaks during the acute-phase) were noted in three of the
animals (Mm0512, Mm0516 and Mm0517). The last two
‘‘controllers’’ showed only occasional VL blips during the
chronic-phase (Mm0303 and Mm0511). However, challenge with
SIVsmE543-3 induced persistent low vaccine VL in Mm0515,
while the challenge virus remained undetectable.
In what we termed as the non-controller group of 4 animals, VL
gradually increased with time (Fig. 4 C). The evolving replicating
viruses were found to consist of the challenge virus in Mm0513,
whereas they were apparently vaccine viruses in the remaining
three (Mm0409, Mm0518 and Mm0304). In the latter three, it
appeared as if vaccine viruses were reactivated upon challenge
with heterologous virus. These three eventually developed AIDS
and were euthanized, whereas Mm0513 has not shown any disease
manifestation .80 weeks pc. These four animals were regarded as
poor or non-controllers.
These results indicate that the deglycosylated, live attenuated
SIV viruses function as effective vaccines and possess potential to
induce near-sterile, long-lasting immunity against the heterologous
virus in a significant, albeit not all vaccinated animals. Also these
results demonstrated that all 4 deglycosylation mutants exhibited
similar vaccine efficacy based on the ratio of controllers and non-
controllers (Figs. 4 B and C).
Adaptive immune responses in vaccinees
In efforts to investigate immune correlates of protection against
the heterologous challenge in vaccinees during acute and chronic
infection, we examined adaptive immune responses against
vaccine and challenge viruses. As described, the levels of NAb
responses against vaccine virus varied among the vaccinees, partly
due to the differences in N-glycosylation in gp120 (Figs. 1 and 2B).
The differences in the NAb responses in vaccinees were
maintained even after challenge with the heterologous virus.
Whereas the D5G-ver2-vaccinated animals elicited the highest
level of NAb, the D3G-vaccinated animals elicited the lowest level
of NAb. In addition, the D5G and D5Gver1-vaccinated animals
elicited intermediate NAb responses (Fig. 5). Regardless of these
differences, all of the vaccinees successfully contained acute-phase
VL, before diverging into controllers and non-controllers during
the chronic infection-phase (Figs. 4 B and C). Thus, vaccine
induced NAb responses did not correlate with protection from
challenge virus infection during either acute or chronic infection.
In addition, we could not detect any appreciable NAb against
SIVsmE543-3 in any of the vaccinees throughout the observation
period (Fig. 5). Although NAb was reasoned to exert immune
pressure driving the emergence of mutants with altered N-
glycosylation in HIV/SIV infections [18,19,20], no significant
association was observed between NAb responses and the
emergence of the mutants in non-controllers (Figs. 4 and 5).
We next examined cellular responses specific to the viral
proteins in the PBMC utilizing the IFN-c ELISPOT assay against
pools of peptides spanning the entire proteins of both SIVsmE543-
3 and SIVmac239. Specific T cell responses to SIVmac239-
peptides paralleled those to SIVsmE543-3-peptides in all of
vaccinees, and therefore vaccine-elicited SIV specific T cells were
assumed to cross-react with SIVsmE543-3 infected cells (Fig. 6).
However, no obvious quantitative correlation was found between
the overall specific T cell responses and either good, poor or the
lack of control of viremia throughout the observation period
(Fig. 4). It is of interest to note that more than half of the SIV
specific T cell responses appeared directed against epitopes
localized within the SIV-Gag protein in most of the vaccinated
animals (Fig. 6) which suggests that a potential association exists
between gag specific T cell response with control of viremia. These
findings are consistent with previous reports that suggest that the
magnitude of Gag-specific T cell response correlates with control
of HIV/SIV viremia in not only HIV-1-infected cohorts [11,21]
but also in macaques included in vaccine studies [8,16].
Taken together, whereas these results indicate no appreciable
correlation between NAb response and control of heterologous
challenge intravenous infection, there may exist a potential role of
virus specific cellular responses in the control of viral replication.
Figure 4. Plasma viral RNA loads in the heterologous SIVsmE543-3 challenge. Three vaccine-naı ¨ve animals (Mm0309, Mm0626, Mm0627)
(A) and 11 vaccinees (B, C) were challenged intravenously with 1000 TCID50 of SIVsmE543-3. The vaccinees were divided into controllers (B) and non-
controllers (C) based on control of vaccine and heterologous challenge infection. VL were determined by two sets of real-time RT-PCR for gag
sequence of SIVsmE543-3 (closed diamonds) and SIVmac239 (open circles) respectively. For analysis of SIV sequence, PBMC and plasma were
collected at the time-points indicated by arrows and arrowheads, respectively. (D) VL of the 11 vaccinees were statistically compared with those of 3
vaccine-naı ¨ve controls at 2, 4, 6 and 10 weeks pc. Significant difference between vaccinees and controls at each time points are shown (Mann-
Whitney test).
doi:10.1371/journal.pone.0011678.g004
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N-glycosylation sites in gp120 by recombination and
single point mutations
In efforts to understand the mechanisms involved in the loss of
control of viremia in the 4 non-controllers, we sequenced the
emerging viruses using PBMC collected at time points indicated by
arrows in Fig. 4 C. Sequence analysis of viruses isolated from
Mm0513 confirmed that only the challenge virus with a 9
nucleotide deletion was replicating in this animal (Fig. 7). Whereas
the vaccine virus was detected in the PBMC from Mm0304
collected at 25 weeks pc, a recombinant virus was predominantly
present in the PBMC samples collected at 45 weeks pc from this
animal (Fig. 7). Viruses with multiple recombinations were also
found in Mm0409 and Mm0518 (Fig. 7). To examine if the
recombination that we detected in the PBMC DNA was
representative of the replicating viruses, we performed nested
PCR utilizing primer pair sets aimed at the detection of putative
recombination sites on RNA obtained from plasma from each
animal (File S1). Consistent with the results obtained from PBMC
DNA, the recombinants were also found in plasma RNA samples
in all 3 animals, whereas only a few SIVsmE543-3 sequences were
detected in Mm0518 (Table 2).
As noted above, while attenuated vaccine viruses have 18 or 20
N-glycosylation sites, the pathogenic strains, SIVmac239 and
SIVsmE543-3 have 23 and 22 N-glycosylation sites, respectively
(Fig. 1). We noticed that the gp120-encoding region of all
replicating viruses in the chronic phase post challenge originated
from the SIVsmE543-3 isolate regardless of recombination (Fig. 7).
This resulted in restoration of N-glycosylation sites, the number of
which was analyzed. We sequenced the PCR products amplified
Figure 5. Neutralizing antibodies (NAb) response in the vaccine recipients. NAb responses against vaccine viruses (closed squares) and
challenge virus (open circles) were measured in CEMx174/SIVLTR-SEAP system. NAb titers were indicated as the reciprocal of the dilutions of the
plasma from the vaccinees yielding 50% inhibition (IC50).
doi:10.1371/journal.pone.0011678.g005
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control animals (the time-points chosen for analysis were shown by
arrowheads in Figs. 4A and C). The newly replicating viruses were
now found to possess restored numbers (.22) of N-glycosylation
sites (Fig. 8). Mutation associated with N-glycosylation in gp120 of
SIVsmE543-3 was a common feature of the SIV that we detected
in non-controllers regardless of the occurrence of the recombina-
tion events. Accordingly, the viruses detected at later time-points
had increased number of N-glycosylation sites compared with
those from earlier time-points. For virus sequences that included
23 to 25 sites, additional N-glycosylation sites were acquired by
single point mutations (Fig. 8). Of note, the addition of N-
glycosylation sites preferentially occurred in the following three
regions: V1, between V2 and the C-loop and V4 (Fig. 8). We also
found a viral sequence with 2 additional N-glycosylation sites that
reside within these hotspots in one of the naı ¨ve control animals
(Mm0626) (Fig. 8). These results indicate that mutations associated
with glycosylation of gp120 were associated with persistent viral
replication during the chronic phase in all of the non-controllers
and one of three naı ¨ve controls. These data suggest that
glycosylation plays a prominent role in optimizing fitness and/or
evasion from vaccine-induced host responses in these viruses.
Discussion
In this study, we examined whether reduction of glycosylation
on viral spikes would allow for more ready access for host immune
responses and thus provide for a new type of live attenuated
vaccine, which would induce more robust anti-viral immune
response and protect outbred rhesus macaques, against heterol-
ogous virus challenge. To evaluate the influence of allelic
differences in host genetic properties on the efficacy of the
Figure 6. SIV specific cellular response in the vaccine recipients. SIV specific T cells were stimulated with overlapping peptides encompassing
the viral proteins (Gag, Pol, Env, and Others: Vif, Vpr, Vpx, Tat, Rev, and Nef) of SIVmac239 and SIVsmE543-3 and the number of spot forming cells
(SFC) per 10
6 PBMC determined utilizing the IFN-c ELISPOT assay. The PBMC samples analyzed for the responses included those collected pre-
vaccination, pre-challenge (4–8 weeks prior to the challenge) and at 3, 14, 30 and 60 weeks pc.
doi:10.1371/journal.pone.0011678.g006
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genes. Irrespective of differences in MHC genotypes, following a
transient primary infection in approximately half of the vaccine
recipients, all 11 vaccinated animals suppressed the acute-phase
viral replication below the level of detection between 4 and 10
weeks pc (Figs. 4 B, C and D). After 10 weeks pc, containment of
challenge virus infection diverged in two ways: 1) the majority (7 of
the 11) of the vaccinated animals continued to control heterolo-
gous virus for more than 80 weeks pc without the contribution of
elite MHC alleles previously associated with spontaneous CD8+ T
cell mediated control of SIV replication in chronic SIV infection
[6,7,22] (Fig. 4 B); 2) however, 4 of the vaccinated animals showed
re-activation of SIV replication (Fig. 4 C) and three eventually
developed AIDS. These results demonstrate that the host
responses induced by these vaccines are capable of protecting
from heterologous challenge virus at least during a limited period
shortly after the challenge (10 weeks) irrespective of the inherited
genetic properties of the host. However due to quantitative and/or
qualitative changes in the protective response during the chronic-
phase, viruses overcome the protective host response and most
likely evolve viral diversity that is resistant to virus specific immune
responses.
The pathogenic viral replication was associated with the
emergence of viruses that were recombinants between the vaccine
virus and the challenge virus SIVsmE543-3 and was associated
with an increased glycosylation of viral spikes (Figs. 7 and 8). On
the other hand, a significant number of the vaccinated animals
controlled the infection with SIVsmE543-3 not only during the
primary-phase but also during the chronic-phase (Fig. 4 B). We
speculate that the properties of the recombinants might be
essential for these viruses to circumvent the protective responses
in these three vaccinees, which were able to control both the
vaccine and the challenge viruses. Interestingly, the recombinant
viruses shared the common part of Pol and Env from SIVsmE543-
3 and that of Gag and Nef from the vaccine viruses (Fig. 7). The
complexity of the recombination patterns between vaccine and
challenge viruses suggest that repeated events of super-infection
with both viruses replicating concurrently must occur to allow for
recombination to occur. Subsequently, only a few viruses that
succeeded in evading vaccine-induced host responses have
managed to replicate to substantial levels in these non-controllers.
These viruses are assumed to have acquired distinctive properties
conferred by the chimera structures that make them different from
the original vaccine and challenge viruses. Viral spikes derived
from SIVsmE543-3 with increased glycosylation are likely essential
for these properties, since all of the SIV sequences examined at
later time points had more than 23 N-glycosylation sites in gp120
of SIVsmE543-3 (Fig. 8). Although the changes of N-glycosylation
sites in gp120 of SIV/HIV have been previously reported to be
associated with escape from neutralizing antibody response
[7,19,20], we did not detect any significant titers of neutralizing
antibodies against the challenge virus in any of the 11 vaccinees
(Fig. 5). Thus, modification of N-glycosylation sites in these viruses
might play a role in inducing anti-viral host responses other than
neutralizing antibody responses, such as antibody-dependent cell-
mediated cytotoxicity (ADCC) or such modifications might lead to
altered viral properties or ‘‘viral fitness’’ such as tissue/cell
tropism, replication levels, and/or stability in these animals.
It remains to be elucidated why an established immunity
capable of containing the viral burst during acute infection
gradually loses its grip over the virus, allowing for the generation of
these mutant viruses. Select genetic properties required for
prevention of emergence of escape mutants and/or viruses with
altered fitness able to overcome vaccine-induced protective host
responses might be lacking in these four animals. Indeed, MHC I
allele A1*0560202 and the ones associated with MHC II
haplotype 89002-p such as A1*01807 and others were identified
only in non-controllers (File S1). Similarly, MHC I alleles such as
A1*0040102, A1*11001, A1*03202 were indentified in controllers
but not non-controllers suggesting immune responses regulated by
MHC genes such as CTL and NK via KIR related mechanisms
might play a role in viral control during the chronic-phase. Our
attempts to identify immunological correlates of protection
suggested that magnitude of overall T cell responses could not
account for either the marked containment of the infection during
the acute-phase or the different outcome of the infection between
controllers and non-controllers during the chronic-phase. Never-
theless, the fact that Gag-specific T cells constitutes more than
Figure 7. Recombination between vaccine and challenge virus.
Nucleotide sequences of SIV fragments amplified by sets of nested PCR
using primers based on SIVsmE543-3 or SIVmac239 to cover the entire
SIV genome except the 59 and 39 terminal sequences (,100 bp).
Representative sequences from integrated results of multiple sequenc-
es of PCR fragments are shown. The sequences detected in Mm0304 at
25 weeks pc were the vaccine virus sequences (top bar indicated by
open box) and the sequences detected in Mm0513 at 55 weeks pc were
the challenge virus sequences (bottom bar indicated by grey box)
except in the case of the latter which contained a 9 bp deletion shown
by triangle. Other represented sequences were recombinant viruses
between vaccine (open boxes) and SIVsmE543-3 (gray boxes). Lines
with arrowheads indicate the sequences that were targeted for nested
PCR to quantify the recombinant viruses and SIVsmE543-3 in the
non-controllers.
doi:10.1371/journal.pone.0011678.g007
Table 2. SIVsmE543-3 derived and recombinant viruses in
non-controllers
a.
Vaccinee Weeks pc SIVsmE543-3 Recombinants
Mm0304 60 0 320
80 0 1600
Mm0409 60 0 200
Mm0518 60 3 60
75 3 200
aViral RNA in plasma was converted to cDNA, serially diluted and subjected to
nested PCR to quantify SIVsmE543-3 and the recombinant viruses between the
vaccine and SIVsmE543-3. Frequencies of SIVs were estimated as the total viral
sequences detected by nested PCR using cDNA synthesized from 0.128 ml of
plasma.
doi:10.1371/journal.pone.0011678.t002
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(Fig. 6) suggest an important role for these responses in the
containment of the heterologous virus infection. The magnitude of
such responses may also be critical during acute infection
illustrated by the association of strong acute cellular response
and rare detection of recombinant virus in one vaccinee Mm0513,
that prevented disease progression (Figs. 4 C and 6).
Efficacy of a live attenuated vaccine against heterologous virus
has also been studied using nef gene deleted mutants including
SIVmac239Dnef [23] and SIVmac239D3 [24] as live attenuated
vaccines. It is difficult to compare those results with results of the
studies reported herein obtained under similar but not exactly the
same conditions. However, a number of differences between the
use of SIVDnef and the studies reported herein were noted: First,
the control of acute-phase viral infection occurred in the vaccinees
with MHC I alleles associated with elite controller, Mamu B*08
and B*17 in the Dnef vaccine study. In contrast, our study
indicated control of the primary infection in all of the vaccinees
irrespective of the diversity of MHC genotypes. Second, the
containment of the challenge virus in the chronic-phase also
appeared to be much less prominent in these two studies. These
differences might stem from the intrinsic properties of the two
types of live attenuated SIV. We have previously reported that
SIVmac239Dnef and SIVmac239 with a functional nef gene
replicate preferentially in B cell areas and T cell areas,
respectively, in peripheral lymph nodes during primary infection
[17]. On the other hand, D5G replicates preferentially in CD4+T
cells in intestinal effector sites such as lamina propria, whereas the
wild-type SIVmac239 replicates in CD4+T cells in inductive sites
such as T cell areas of secondary lymphatic tissues. These subtle
differences of tissue and cell tropism suggests that the mechanisms
of attenuation may differ between D5G and SIVmac239Dnef and
may further explain why the latter is likely more pathogenic than
the former. In addition, the differences in the susceptibility of the
macaques to SIV, estimated by the magnitude of peak VL during
primary infection and set point VL, could be another factor that
influenced the results of the studies. In nonhuman primate model
for AIDS, the properties of SIV strains and the origin of macaques
appear to affect the results and interpretation of the data from the
experiments. Judged from previous studies from a number of other
laboratories including ours that have utilized Burmese [8,16,17]
and Indian macaques [6,25,26,27] respectively, Burmese rhesus
macaques infected with SIVmac239 tend to have lower set point
VL and require more time to develop AIDS than Indian rhesus
macaques. Thus, these differences might have allowed us to
discover potent protective host responses against heterologous
virus elicited by a deglycosylated live-attenuated vaccine. On the
other hand, this study also demonstrates that Burmese macaques
were more susceptible to SIVsmE543-3 than SIVmac239 (Figs. 3
and 4 A). In fact, these results indicate that SIVsmE543-3 and
SIVmac239 might form an excellent model of heterologous
challenge virus and a template virus to create vaccine viruses.
These results also underline that macaque susceptibility to SIV
might be more SIV strain specific than previously considered.
In summary, we report here for the first time, the induction of
potent protective immunity against heterologous challenge by live
attenuated SIV in macaques with a diverse MHC genetic
background. Our system provides a unique and robust experi-
mental paradigm for defining the potential immunological
correlates of protection, assessing cross-subtype protection and
designing HIV vaccines. However, emergence of pathogenic
revertants from live attenuated SIVs by spontaneous mutations as
well as by recombination has often been encountered in macaque
AIDS models [23] [28] and certainly during our study. Thus,
while a live vaccine strategy is clearly not a viable approach to
actual HIV vaccine development, much can be learnt with regards
to the mechanisms involved. As noted above, continuous
stimulation of the host immune system by persistently infected
vaccine virus at low levels may be a key factor for maintaining
protective immunity not only against homologous but also
heterologous SIV over a long period. We believe that creating
such a condition, for instance, by a virus vector capable of
establishing a persistent infection may be one strategy that may
lead to the development of an effective vaccine against HIV.
Minimally, the heterologous virus challenge model described
herein provides a powerful tool to attempt to identify the potential
mechanisms that lead to protective versus non-protective immu-
nity. We reason that such events are likely to have occurred during
the acute phase of ‘‘vaccine’’ virus replication which sets the course
for the eventual response of the animals to the heterologous
challenge virus. A detailed study of events that transpire during the
acute infection period may provide unique insights on this issue.
Materials and Methods
Mean distance of amino acid sequences of HIV-1 group
M subtypes and amino acid differences between
SIVmac239 and SIVsmE543-3
The complete genome sequence alignments consist of 368 HIV-
1 isolates (59 subtype A, 71 subtype B, 148 subtype C, 39 subtype
D, 6 subtype F1, 3 subtype F2, 6 subtype G, 3 subtype H, 2
subtype J, 2 subtype K, 15 CRF01_AE, and 14 CRF02_AG) as
determined from HIV sequence database (http://www.hiv.lanl.
gov/cgi-bin/NEWALIGN/align.cgi) were used for these analyses.
The alignment data was coordinated with HXB2-LAI-IIIB. These
data led to the identification of nine coding regions, as determined
utilizing the MEGA4 software [29]. We estimated the number of
amino acid differences per site from averaging the over all
sequence pairs between and within each subtype or CRF, and also
mean diversity. All results are based on the pairwise analysis of the
sequences, and standard error estimates were obtained by a
bootstrap procedure (500 replicates). All positions containing gaps
and missing data were eliminated from the dataset. The amino
acid comparisons in each viral protein between SIVmac239
(Genbank accession no. M33262) and SIVsmE543-3 (Genbank
accession no. U72748) were analyzed by Clustal W (http://www.
clustal.org).
Attenuated vaccine viruses and challenge virus
The molecular pathogenic clone of SIVmac239 [30] and its
derived deglycosylated mutants used in this study are depicted in
Figure 8. N-glycosylation sites in gp120 of the emerged viruses. The putative N-glycosylation sites (vertical bars) in gp120 were analyzed
based on sequencing data from PBMC and plasma samples obtained from non-controllers. The red lines indicate SIVmac239 or vaccine virus
sequences, and blue lines indicate SIVsm534-3 sequences. The notations (2) and (+) indicate the loss and addition of N-glycosylation site
respectively. The triangle sign indicates a 3 amino acid deletion located within the V1 region found in the Mm0513. The numbers shown besides (+)
denote the amino acid sequence numbers for hotspots of addition of N-glycosylation sites based on SIVsmE543-3 Env amino acid sequence
(accession no. U72748). The total number of N-glycosylation sites found in each sequence was shown on the right, and the numbers in parenthesis
indicate the number of sequences detected by PCR.
doi:10.1371/journal.pone.0011678.g008
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SIVmac239 infectious DNA clone so that the asparagine residues
for the N-glycosylation sites at aa 79, 146, 171, 460 and 479 in
gp120 were converted to glutamine residues [2,3]. The D5G-ver1,
D5G-ver2 and D3G were also constructed by site-directed
mutagenesis from the series of deglycosylated mutants reported
previously [2]. The stocks of deglycosylated mutants were
prepared by DNA transfection of respective proviral DNAs into
293T cells. The stock of SIVsmE543-3 was prepared as previously
described [4]. These virus stocks were propagated in phytohe-
magglutinin-stimulated peripheral PBMC from rhesus macaques
as previously described [3,16].
Animals
Juvenile rhesus macaques originating from Burma were used
following negative results of screening for SIV, simian T-cell
lymphotropic virus, B virus, and type D retrovirus infection prior
to study inception. All animals were housed in individual cages
and maintained according to the rules and guidelines for
experimental animal welfare as outlined by National Institute of
Infectious Diseases and National Institute of Biomedical Innova-
tion, Japan. Full details of the study were approved (Approval
number: 507006) by National Institute of Infectious Diseases
Institutional Animal Care and Use Committee in accordance with
the recommendations of the Weatherall report. Early endpoints
are adopted including frequent monitoring of viral loads and
immunological parameters, and humane euthanasia is conducted
once any manifestation of clinical AIDS or signs of fatal disease is
noted.
Vaccination and challenge infection
Three animals per group were intravenously inoculated with
100 TCID50 of either of 4 deglycosylation mutants (D5G, D5G-
ver1, D5G-ver2 and D3G) as shown in Fig. 1. At 40 weeks post
infection, 4 SIV-infected animals: Mm0301 (D5G), Mm0513
(D5G-ver1), Mm0307 (D5G-ver2), Mm0304 (D3G) and three
naive animals (Mm0608, Mm0521, and Mm0522) were intrave-
nously inoculated with 1000 TCID50 of SIVmac239 for purposes
of homologous virus challenge studies.
To examine the efficacy of the live attenuated vaccine against
heterologous virus, 11 vaccinees were intravenously inoculated
with 1000 TCID50 of SIVsmE543-3.3 as follows: Mm0517 (D5G),
Mm0511 (D5G-ver1), and Mm0512 (D5G-ver2) were challenged
at 50 weeks post vaccination with the deglycosylation mutant;
Mm0409 (D5G), Mm0303 (D5G-ver1), and Mm0518 (D5G-ver2)
were challenged at 61 weeks post vaccination; Mm0515 (D3G) and
Mm0516 (D3G) were challenged at 117 weeks post vaccination. 3
naı ¨ve animals (Mm0309, Mm0626, Mm0627) were infected with
SIVsmE543-3 as vaccine-naı ¨ve controls. Furthermore, three of
SIVmac239-challenged animals, Mm0301, Mm0513 and
Mm0304 (Mm0307 died with a SIV-infection-unrelated cause)
were re-challenged with SIVsmE543-3 at 117 weeks post
vaccination and 77 weeks post SIVmac239 challenge.
Plasma viral load measurements
SIV infection was monitored by measuring the plasma viralRNA
load using a highly sensitive quantitative real-time RT-PCR. Viral
RNA was isolated from plasma samples from infected animals using
MagNA PureCompact Nucleic Acid Isolation Kit (Roche Diagnos-
tics). Real-time RT-PCR was performed by using QuantiTec Probe
RT-PCR kit (Qiagen) and Sequence detection system SDS7000
(Applied Biosystems). To detect SIVmac239 gag and SIVsmE543-3
gag separately, primers and probe sets were synthesized as follow;
SIVsmE543-3 gag specific primers: 59- FAM-GCAGAGGAG-
GAAATTACCCAGTGC-39,5 9-CAATTTTACCCAAGCATT-
TAATGTT- TAMRA- 39 and probe 59-TGTCCACCTACCCT-
TAAGTCCAA-39, SIVmac239 specific gag primers: 59-GCA-
GAGGAGGAAATTACCCAGTAC-39,5 9-CAATTTTACCCA-
GGCATTTAATGTT-39 and probe 59-FAM-TGTCCACCTGC-
CATTAAGTCCCGA-TAMRA-39. These primers and probes do
not cross-react with SIVmac239 RNA and SIVsmE543-3 RNA.
The detection sensitivity of plasma viral RNA by this method was
calculated to be 100 viral RNA copies per ml of plasma.
Sequencing of SIV RNA and proviral DNA
Viral RNA was isolated using MagNA PureCompact Nucleic
Acid Isolation Kit (Roche Diagnostics) and cDNA was synthesized
with two-step qRT-PCR kit (Invitrogen). PBMC from vaccine
recipients were suspended with lysis buffer (10mM Tris 0.5% NP-
40 and 0.5% Tween20) with Proteinase K (200 mg/ml), and
incubated at 55uC for 1 hour, then heat-inactivated at 95uC for
5 min. Serial 10-fold diluted cDNA or cell lysate was subjected to
nested PCR with the Ex-Taq PCR kit (Takara, Tokyo, Japan) with
the following condition: 1 cycle of 97uC for 1 min. and then 25
cycles of amplification (94uC for 30 s, 55uC for 30 s, 72uC for
2.5 min) and 72uC for 10 min. and then 4uC for 5 min. Primers
were designed to target the several overlapping sequences
spanning the open reading frames of SIVmac239 or
SIVsmE543-3 as shown in File S1. Positive PCR products were
sequenced by using BigDye terminator cycle sequencing kits
(Applied Biosystems) and analyzed by using ABI3100 or ABI
3130xl Genetic Analyzer (Applied Biosystems). Sequences were
assembled using ATGC version 4.2 (Genetyx Corporation).
SIV specific T cell responses
The T cells in the animals were examined for virus specific
cellular response against the vaccine virus and the challenge virus
by using pooled peptides covering overlapping sequences of all
viral proteins of SIVmac239 and SIVsmE543-3 respectively.
Briefly, cryopreserved PBMC were thawed, resuspended at 2610
6
cells/ml in R10 (RPMI1640 supplemented with 10% heat-
inactivated FCS, 55 mM 2-mercaptoethanol, 50 U/ml penicillin
and 50 mg/ml streptomycin), and rested for 2 h at 37uC. The cells
were washed and aliquots of 10
5 cells were stimulated with each
pool of peptides at a final concentration of 2 mg/ml in an anti-
IFN-g Ab-coated plate overnight. ELISPOT assay for the
detection of IFN-g secreting cells were performed using a
commercial ELISPOT kit (U-CyTech Bioscience). Peptides based
on sequences of SIVmac239 viral proteins were synthesized by the
Microchemical Facility, Emory University School of Medicine,
Atlanta, GA, USA. Peptides based on the sequences of
SIVsmE543-3 viral proteins were synthesized by Sigma-Aldrich
Japan.
Neutralization assay
Virus neutralizing antibodies were tested according to a
protocol using CEMx174/SIVLTR-SEAP cells [31] as described
previously [3]. Serially diluted heat-inactivated plasma was
tested for inhibition of the corresponding vaccine virus or the
challenge virus (SIVsmE543-3) in CEMx174/SIVLTR-SEAP
cells. SEAP activity in the culture supernatant was assayed using
a commercial SEAP reporter gene assay chemiluminescent kit
(Roche Diagnostics).
Statistical analysis
Correlation analysis was performed using Spearman’s non-
parametric rank test and Mann-Whiney ‘U’ test by using Graph
Deglycosylated SIV Vaccine
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significant when P values were ,0.05.
DNA sequence data deposition
The SIV sequences reported in this paper have been deposited
in the DNA Data Bank of Japan (accession nos. AB553915 to
AB554013).
Supporting Information
File S1
Found at: doi:10.1371/journal.pone.0011678.s001 (0.28 MB
PDF)
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